COVID-19: Roche AG launches antigen rapid test
Roche has announced to launch a SARS-CoV-2 point-of-care antigen test this month co-developed with SD Biosensor Inc. (South Korea).
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
Entries by Thomas Gabrielczyk
Unilever to replace fossil carbon in cleaning products
/in News/by Thomas GabrielczykUnilever has announced to invest 1bn globally to eliminate fossil fuels as a source of carbon in its cleaning products by 2030.
Bioversys bags 17.7m financing
/in News/by Thomas GabrielczykSwiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens.
Sotio licences Unum Therapeutics CAR-T cell portfolio
/in News/by Thomas GabrielczykPPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics.
Polyphor partners with Fosun Pharma
/in News/by Thomas GabrielczykPolyphor AG has licenced its metastatic cancer drug balixafortide to Fosun Pharma Co Ltd to market the drug exclusively in China.
Engitix Ltd. lands US$500m deal with Takeda in fibrosis
/in News/by Thomas GabrielczykBritish fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
Moderna set to deliver COVID-19 jab to the EU
/in News/by Thomas GabrielczykUS experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2
Scientists map ulcerative colitis
/in News/by Thomas GabrielczykScientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments.
COVID-19: Roche and Regeneron join forces
/in News/by Thomas GabrielczykRoche and Regeneron have signed an manufacturing and distribution agreement on Regenerons Phase II therapeutic antibody for the treatment of COVID-19.
Aicuris to launch AiCubator to fight AMR
/in News/by Thomas GabrielczykAntinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.